Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Use of rituximab to decrease panel-reactive antibodies.

Ian C Balfour1, Andrew Fiore, Ralph J Graff

  • 1Division of Cardiology, Department of Pediatrics, St. Louis University Health Sciences Center, St. Louis, Missouri 63104, USA. balfoui@slu.edu

The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
|May 18, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report.

Blood advances·2025
Same author

Outcomes following matched sibling donor transplantation for severe combined immunodeficiency: a report from the PIDTC.

Blood advances·2025
Same author

Clinical and Molecular Characteristics of X-Linked Agammaglobulinemia Patients 55 Years or Older.

The journal of allergy and clinical immunology. In practice·2025
Same author

Applying the Social Ecological Model to Explore HIV-Related Stigma in Florida: A Qualitative Study.

Stigma and health·2025
Same author

Omenn syndrome in a 10-month-old male with athymia and VACTERL association.

The journal of allergy and clinical immunology. Global·2023
Same author

Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD.

Blood·2023
Same journal

Alveolar macrophage activation and polarization signatures in stable lung transplant recipients and chronic lung allograft dysfunction.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same journal

Distinct Metabolomic and Lipidomic Profiles Across Donation after Circulatory Death Recovery Strategies Reveal a Common Signature Associated with Primary Graft Dysfunction.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same journal

Antibody-mediated rejection after heart transplantation: diagnostic gaps, suboptimal outcomes, and emerging tools.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same journal

What sotatercept can teach us about the right ventricle in pulmonary arterial hypertension.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same journal

The Future of Heart Transplant Data Science Requires Common Data Models.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same journal

From Guideline to Practice: Operationalizing Telomere Length Testing in ILD and Lung Transplantation.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
See all related articles

Rituximab effectively reduced pre-formed antibodies in a pediatric heart transplant patient, potentially lowering rejection risk. This approach may improve outcomes for children needing organ transplants.

Area of Science:

  • Immunology
  • Transplantation Science
  • Pediatric Cardiology

Background:

  • Pre-formed antibodies pose a significant risk for organ transplant rejection.
  • Identifying strategies to mitigate this risk is crucial for successful transplantation.

Observation:

  • This report details the use of rituximab in a pediatric heart transplant recipient.
  • Rituximab was administered to reduce the level of pre-formed antibodies.

Findings:

  • The treatment successfully decreased the percentage of pre-formed antibodies in the patient.
  • This reduction is a key step in preventing antibody-mediated rejection.

Implications:

  • Rituximab may be a viable therapeutic option for managing pre-formed antibodies in pediatric transplant candidates.

Related Experiment Videos

  • This could lead to improved graft survival and long-term outcomes in pediatric organ transplantation.